Stephen Trowbridge Net Worth

The estimated Net Worth of Stephen A Trowbridge is at least $2.71 Million dollars as of 17 July 2024. Mr. Trowbridge owns over 11,142 units of Angiodynamic Inc stock worth over $1,317,881 and over the last 10 years he sold ANGO stock worth over $318,324. In addition, he makes $1,075,640 as Chief Financial Officer and Executive Vice President at Angiodynamic Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Trowbridge ANGO stock SEC Form 4 insiders trading

Stephen has made over 15 trades of the Angiodynamic Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 11,142 units of ANGO stock worth $82,674 on 17 July 2024.

The largest trade he's ever made was exercising 14,758 units of Angiodynamic Inc stock on 15 July 2022 worth over $235,390. On average, Stephen trades about 1,893 units every 61 days since 2015. As of 17 July 2024 he still owns at least 177,612 units of Angiodynamic Inc stock.

You can see the complete history of Mr. Trowbridge stock trades at the bottom of the page.

Stephen Trowbridge biography

Stephen A. Trowbridge J.D. serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Trowbridge joined AngioDynamics as Corporate Counsel in 2008, was promoted to Vice President and General Counsel in 2010, and subsequently promoted to Senior Vice President, General Counsel in 2013. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. Mr. Trowbridge began his career with Cadwalader, Wickersham & Taft, LLP in the firm's Mergers and Acquisitions and Securities Group. Mr. Trowbridge received a Bachelor of Science in Science and Technology Studies from Rensselaer Polytechnic Institute, a Juris Doctor from the University of Pennsylvania Law School, and a Master of Business Administration from Duke University's Fuqua School of Business.

What is the salary of Stephen Trowbridge?

As the Chief Financial Officer and Executive Vice President of Angiodynamic Inc, the total compensation of Stephen Trowbridge at Angiodynamic Inc is $1,075,640. There are 3 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.

How old is Stephen Trowbridge?

Stephen Trowbridge is 46, he's been the Chief Financial Officer and Executive Vice President of Angiodynamic Inc since 2020. There are 24 older and 2 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.

What's Stephen Trowbridge's mailing address?

Stephen's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.

Insiders trading at Angiodynamic Inc

Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.

What does Angiodynamic Inc do?

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie

Complete history of Mr. Trowbridge stock trades at Angiodynamic Inc

Angiodynamic Inc executives and stock owners

Angiodynamic Inc executives and other stock owners filed with the SEC include:

• James Clemmer,
  President, Chief Executive Officer, Director
• James C. Clemmer,
  CEO, Pres & Director
• Chad Campbell,
  Senior Vice President and General Manager, Vascular Access
• Stephen Trowbridge,
  Chief Financial Officer, Executive Vice President
• Scott Centea,
  Senior Vice President, General Manager, VIT
• Stephen A. Trowbridge,
  Exec. VP & CFO
• David Helsel,
  Senior Vice President - Global Operations
• Brent Boucher,
  Senior Vice President and General Manager, Oncology/Surgery
• David D. Helsel,
  Sr. VP of Global Operations and R&D
• Warren G. Nighan,
  Sr. VP of Quality & Regulatory Affairs
• Chad T. Campbell,
  Sr. VP & GM of Vascular Access Global Bus. Unit
• Howard Donnelly,
  Independent Chairman of the Board
• Dennis Meteny,
  Independent Director
• Wesley Johnson,
  Independent Director
• Eileen Auen,
  Independent Director
• Jan Reed,
  Independent Director
• Karen Licitra,
  Independent Director
• Michael Tarnoff,
  Independent Director
• Kim Seabury,
  Senior Vice President, Information Technology
• Warren Nighan,
  Senior Vice President Quality and Regulatory Affairs
• Benjamin Davis,
  Senior Vice President Business Development
• Marna Bronfen-Moore,
  Senior Vice President of Human Resources
• Scott Centea,
  Sr. VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease
• Kim L. Seabury,
  Sr. VP of Information Technology
• Marna I. Bronfen-Moore,
  Sr. VP of HR
• Benjamin H. Davis,
  Sr. VP of Bus. Devel.
• Richard C. Rosenzweig,
  Sr. VP, Gen. Counsel & Company Sec.
• Capital Partners Gp, Llc Av...,
  
• Steve La Porte,
  Director
• Jeffrey Gold,
  Director
• Michael Greiner,
  EVP and CFO
• Sriram Venkataraman,
  Director
• Kevin J Gould,
  Director
• David F Burgstahler,
  Director
• Charles R Greiner,
  VP - Global Franchise
• Laura Piccinini,
  SVP International
• Stark Richard,
  SVP, GM - Oncology
• Robert Arthur Simpson,
  SVP/GM, Global Vascular
• David P Meyers,
  Director
• Gregory D Casciaro,
  Director
• Matthew C Kapusta,
  SVP, Business Development
• George W. Iv Bourne,
  SVP and CTO
• Stephen Mc Gill,
  SVP - General Manager
• Mark T Frost,
  EVP and CFO
• John Soto,
  VP - OUS Sales
• Lynda M. Wallace,
  SVP - Business Development
• Vincent Bucci,
  Director
• Scott J. Solano,
  Senior Vice Preisdent - CTO
• Robert D Mitchell,
  Executive VP and COO
• Shawn P Mc Carthy,
  SVP - General Manager
• Robert M Rossell,
  VP - Marketing
• Robert E Flaherty,
  Director
• William M Appling,
  VP - Research
• Brian Kunst,
  VP - Regulatory Affairs
• Peter J Graham,
  Director
• D Joseph Gersuk,
  SVP - CFO
• Paul J Shea,
  VP - Sales
• Eamonn P Hobbs,
  President and CEO
• Joseph G Gerardi,
  VP - CFO
• Alan Panzer,
  SVP, GM - Vascular
• Harold Mapes,
  VP - Operations
• Daniel Recinella,
  VP - Product Development
• Paul S Echenberg,
  Director
• Richard Scott Etlinger,
  SRVPGLOP
• Charles Thomas Orsatti,
  Director
• Joseph Devivo,
  President and CEO
• Jan Keltjens,
  President & CEO
• Howard S Stern,
  Director
• Linda B Stern,
  10% owner
• Em Inc Ez,
  10% owner
• Richard C Rosenzweig,
  SVP and General Counsel
• Dave Helsel,
  SVP Global Operations and R&D
• Lorinda Burgess,